{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.52","upperLimit":"91.55","value":"89.31"},{"groupId":"OG001","lowerLimit":"85.39","upperLimit":"92.50","value":"89.50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"622"},{"groupId":"OG001","value":"308"}],"units":"Participants"}],"description":"PSA progression was defined as the first increase in PSA of 25% or greater and 2 ng/mL or greater above the nadir with confirmation by a second consecutive PSA measurement at least 3 weeks later. For participants without declining PSA from baseline, a PSA increase of ≥ 25% and ≥ 2 ng/mL from baseline beyond 12 weeks was considered PSA progression. The rate of progression-free survival was estimated using the Kaplan-Meier method and reported as percentage of participants.","dispersionType":"95% Confidence Interval","groups":[{"description":"Relugolix 120-mg tablet administered orally once daily for 48 weeks following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG000","title":"Relugolix"},{"description":"Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan), every 3 months by subcutaneous injection.","id":"OG001","title":"Leuprolide Acetate"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Week 49 Day 1 (Day 337)","title":"Rate Of PSA Progression-free Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}